Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaap Verweij

Showing results (201-210 of 234) with videos related to

Pageof 24
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2007
Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropeniaJessica M van der Bol, Ron H J Mathijssen, Walter J Loos, et al.
Molecular Cancer Therapeutics|June 11, 2009
Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumorsRichard D Baird, Jos Kitzen, Paul A Clarke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignanciesRonald Hoekstra, Herlinde Dumez, Ferry A L M Eskens, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2010
Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulationMaja J A de Jonge, Marije Slingerland, Walter J Loos, et al.
European Journal of Cancer (Oxford, England : 1990)|June 2, 2014
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led studySophie Postel-Vinay, Laurence Collette, Xavier Paoletti, et al.
European Journal of Cancer (Oxford, England : 1990)|July 25, 2024
Empowering effective biomarker-driven precision oncology: A call to actionMark Lawler, Peter Keeling, Olga Kholmanskikh, et al.
Clinical Pharmacology and Therapeutics|August 8, 2006
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinibErin R Gardner, Herman Burger, Ron H van Schaik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2005
Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancerRonald Hoekstra, Filip Y F L de Vos, Ferry A L M Eskens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2012
A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patientsKarel Eechoute, Martin N Fransson, An K Reyners, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2006
A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignanciesChooi P Lee, Maja J A de Jonge, Anne E O'Donnell, et al.
Pageof 24

Showing results (201-210 of 234) with videos related to

Sort By:
Pageof 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2007
Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropeniaJessica M van der Bol, Ron H J Mathijssen, Walter J Loos, et al.
Molecular Cancer Therapeutics|June 11, 2009
Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumorsRichard D Baird, Jos Kitzen, Paul A Clarke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignanciesRonald Hoekstra, Herlinde Dumez, Ferry A L M Eskens, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2010
Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulationMaja J A de Jonge, Marije Slingerland, Walter J Loos, et al.
European Journal of Cancer (Oxford, England : 1990)|June 2, 2014
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led studySophie Postel-Vinay, Laurence Collette, Xavier Paoletti, et al.
European Journal of Cancer (Oxford, England : 1990)|July 25, 2024
Empowering effective biomarker-driven precision oncology: A call to actionMark Lawler, Peter Keeling, Olga Kholmanskikh, et al.
Clinical Pharmacology and Therapeutics|August 8, 2006
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinibErin R Gardner, Herman Burger, Ron H van Schaik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2005
Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancerRonald Hoekstra, Filip Y F L de Vos, Ferry A L M Eskens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2012
A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patientsKarel Eechoute, Martin N Fransson, An K Reyners, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2006
A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignanciesChooi P Lee, Maja J A de Jonge, Anne E O'Donnell, et al.
Pageof 24